|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:John_C._Jacobs
|
|
gptkbp:collaboratedWith
|
gptkb:SK_Bioscience
gptkb:Takeda_Pharmaceutical_Company
gptkb:Serum_Institute_of_India
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
670002401
|
|
gptkbp:developedVaccineFor
|
gptkb:COVID-19
gptkb:influenza
|
|
gptkbp:focusesOn
|
infectious diseases
vaccine development
|
|
gptkbp:founded
|
1987
|
|
gptkbp:foundedBy
|
gptkb:John_Spears
Gale Smith
|
|
gptkbp:fundedBy
|
gptkb:U.S._government
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
|
|
gptkbp:headquartersLocation
|
gptkb:Gaithersburg,_Maryland,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US6700024010
|
|
gptkbp:keyPerson
|
gptkb:John_C._Jacobs
Filip Dubovsky
Gale Smith
Gregory Glenn
Silvia Taylor
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:logo
|
Novavax logo.svg
|
|
gptkbp:marketCap
|
varies (publicly traded)
|
|
gptkbp:notableEvent
|
COVID-19 pandemic vaccine development
|
|
gptkbp:notableProduct
|
NanoFlu
Nuvaxovid (NVX-CoV2373)
ResVax
|
|
gptkbp:numberOfEmployees
|
~1500 (2023)
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:previousName
|
gptkb:Novavax
|
|
gptkbp:product
|
gptkb:Covovax
gptkb:Nuvaxovid
|
|
gptkbp:receivedEmergencyUseAuthorization
|
gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:NVAX
|
|
gptkbp:subsidiary
|
Novavax AB
|
|
gptkbp:technology
|
gptkb:Matrix-M_adjuvant
recombinant nanoparticle vaccine
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_NVAX
|
|
gptkbp:type
|
public
|
|
gptkbp:website
|
https://www.novavax.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:_NVAX
gptkb:NVAX
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novavax, Inc.
|